Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 18, 2026 09:00 ET | Source: Muscular Dystrophy Association

Nationwide MDA Shamrocks Campaign Advances Independence for People Living with Rare Neuromuscular Conditions

New York, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced its nationwide MDA Shamrocks campaign, uniting with retail partners across the country to make a...
February 17, 2026 09:00 ET | Source: Muscular Dystrophy Association

Muscular Dystrophy Association Announces Łukasz Sznajder, PhD, MSc, to Receive Inaugural MDA Research Momentum Award

New York, Feb. 17, 2026 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Łukasz Sznajder, PhD, MSc, Assistant Professor, Department of Chemistry and Biochemistry,...
February 03, 2026 15:03 ET | Source: Muscular Dystrophy Association

Bipartisan Congressional Action Advances Critical Programs for Rare Neuromuscular Disease Research and Care

Washington, D.C., Feb. 03, 2026 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today applauded the bipartisan passage of the annual federal funding bill that sustains critical...
January 27, 2026 09:00 ET | Source: Muscular Dystrophy Association

Organizations Join Forces to Map How Human Muscle Regenerates

New York, Jan. 27, 2026 (GLOBE NEWSWIRE) -- A pivotal scientific collaboration born out of the Muscular Dystrophy Association’s (MDA) Muscle Regeneration Summit is advancing a first-of-its-kind...
January 26, 2026 09:00 ET | Source: Muscular Dystrophy Association

Muscular Dystrophy Association Marks Rare Disease Day by Spotlighting Community Stories Driving Progress in Research, Care, and Advocacy

New York, Jan. 26, 2026 (GLOBE NEWSWIRE) -- In recognition of Rare Disease Day on February 28, the Muscular Dystrophy Association (MDA) is sharing powerful community stories throughout the month...
January 14, 2026 09:00 ET | Source: Muscular Dystrophy Association

Muscular Dystrophy Association’s Legacy Awards Honor Innovators in Clinical and Scientific Research, and Community Impact at the 2026 MDA Clinical & Scientific Conference in March

New York, Jan. 14, 2026 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) is proud to announce the recipients of the 2026 MDA Legacy Awards, recognizing excellence in scientific and...
December 10, 2025 09:00 ET | Source: Muscular Dystrophy Association

Muscular Dystrophy Association Announces More Than $2.7 Million For Research Grants to Advance Breakthroughs Across Neuromuscular Diseases

New York, Dec. 10, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced more than $2.7 million in new research grants to advance groundbreaking discoveries across...
December 08, 2025 09:00 ET | Source: Muscular Dystrophy Association

John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), to Deliver Keynote Address on the Future of Biotech and Rare Disease Innovation at the 2026 MDA Clinical & Scientific Conference

New York, Dec. 08, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today that John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), will...
December 03, 2025 08:00 ET | Source: Arrakis Therapeutics

Arrakis Therapeutics Presents Data Highlighting Progress of Oral RNA-targeted Small Molecule to Treat Myotonic Dystrophy Type 1 (DM1)

Preclinical in vivo data demonstrate hyper-precise mechanism directly targets the disease-causing mRNA repeats leading to correction of splicing defects and reversal of myotonia Oral administration...
November 24, 2025 22:21 ET | Source: Muscular Dystrophy Association

Muscular Dystrophy Association Calls FDA Approval of Novartis’ Itvisma (onasemnogene abeparvovec-brve) a Major Step Forward for the Spinal Muscular Atrophy Community

New York, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today called the U.S. Food and Drug Administration’s approval of Itvisma (onasemnogene abeparvovec-brve),...